| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/MOL.52.6.1034 |
| P698 | PubMed publication ID | 9415713 |
| P50 | author | Magnus Ingelman-Sundberg | Q5823202 |
| P2093 | author name string | M Hidestrand | |
| M Ingelman-Sundberg | |||
| M Oscarson | |||
| I Johansson | |||
| P433 | issue | 6 | |
| P304 | page(s) | 1034-1040 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function | |
| P478 | volume | 52 |
| Q40920371 | A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). |
| Q40673843 | Allele-specific long-range PCR/sequencing method for allelic assignment of multiple single nucleotide polymorphisms |
| Q44396463 | Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes |
| Q88763523 | CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712 |
| Q46564749 | CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing |
| Q58698638 | CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort |
| Q41987357 | CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting |
| Q90302004 | CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels |
| Q36053309 | CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype |
| Q22254414 | Characterization and functional analysis of two common human cytochrome P450 1B1 variants |
| Q37380190 | Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity |
| Q54193657 | Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects. |
| Q37513508 | Cytochrome P450 2D6. |
| Q35584152 | Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry |
| Q36558437 | Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania |
| Q28207097 | Estrogen receptor alpha polymorphisms and renal cell carcinoma--a possible risk |
| Q33533987 | Functional consequences of polymorphism of xenobiotic metabolising enzymes |
| Q35682961 | Genes associated with addiction: alcoholism, opiate, and cocaine addiction |
| Q35922156 | Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity |
| Q34355362 | Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes |
| Q34232408 | Genetic variability in susceptibility and response to toxicants |
| Q35566353 | Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms |
| Q52277603 | Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. |
| Q33777963 | In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane |
| Q51620668 | Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals. |
| Q37433387 | Mammalian cytochrome P450 enzymes catalyze the phenol-coupling step in endogenous morphine biosynthesis |
| Q28543572 | Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels |
| Q35172002 | Pharmacogenetics in Ghana: reviewing the evidence |
| Q35127786 | Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine |
| Q33702276 | Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment |
| Q35035608 | Polymorphism of cytochrome P450 and xenobiotic toxicity |
| Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
| Q45992265 | Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. |
| Q37037058 | Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors |
| Q44057989 | Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. |
| Q74707374 | Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma |
| Q46922848 | The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype |
| Q44188968 | The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations |
| Q37178666 | The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease |
| Q59614218 | Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 |
Search more.